United States Cell Regeneration Medicine Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Astellas Pharma, Roche Ltd, Baxter International Inc and Vertex Pharmaceuticals

Cell Regeneration Medicine Market reached US$ 34.3 billion in 2023 and is expected to reach US$ 90.1 billion by 2031, growing at a CAGR of 12.8% during the forecast period 2024-2031.

According to DataM Intelligence Comprehensive Report has released its latest report on the "Cell Regeneration Medicine Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/cell-regeneration-medicine-market?sg

Industry Latest News 2025:

✅ 2025-01-06: Altaris completed acquisition of Minaris Regenerative Medicine (including Minaris operations in the U.S., Japan and Germany).

✅ 2025-03-06: Orgenesis announced acquisition of certain Neurocords LLC assets to strengthen its spinal-cord / regenerative portfolio.

✅ 2025-03-31: Lynch Regenerative Medicine acquired REGRANEX® Gel and exclusive rights for recombinant PDGF use in soft-tissue regeneration (distribution transition from Smith & Nephew through Aug 2025).

✅ 2025-01-06: As part of the Altaris-Minaris deal, Minaris' Japan operations were included in the transaction (impacting Japan CDMO/regenerative-manufacturing capacity).

✅ 2025-03-17: AstraZeneca agreed to acquire Belgian in-vivo CAR-T specialist EsoBiotec (deal up to ~$1bn) - a significant European M&A move in cell therapy.

✅ 2025-01-06: Minaris' German entity was included in the Altaris acquisition (affecting European CDMO/regenerative manufacturing footprint).

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cell-regeneration-medicine-market?sg

Market Geographical Share:

North America dominates the market, led by the United States, due to a robust biotechnology sector, high adoption of stem cell therapies, and significant government funding for regenerative medicine research.

Europe follows closely, with active participation from countries like Germany, the UK, and France, supported by favorable regulatory frameworks and advanced clinical trial infrastructure.

In the Asia-Pacific region, rapid expansion is underway, fueled by increasing healthcare expenditure, a growing elderly population, and rising research activity in countries such as Japan, South Korea, and China. Japan remains a pioneer in regenerative medicine regulation, while China is investing heavily in stem cell and gene therapy facilities.

Market Drivers:

✅ Rising Prevalence of Chronic Diseases: The growing incidence of degenerative conditions such as cardiovascular disorders, diabetes, and neurodegenerative diseases has accelerated the demand for regenerative therapies.

✅ Advancements in Stem Cell Research: Continuous innovations in stem cell biology, tissue engineering, and biomaterials are improving treatment outcomes and expanding clinical applications.

✅ Supportive Government Initiatives: Increasing public and private funding, along with regulatory approvals for clinical trials and therapy commercialization, is driving global market expansion.

✅ Technological Integration: The integration of 3D bioprinting, AI, and CRISPR gene editing in cell regeneration processes enhances precision and efficacy in personalized medicine.

✅ Growing Geriatric Population: The aging global population, particularly in developed countries, is boosting demand for regenerative treatments to address age-related cellular damage.

✅ Rising Investment in Healthcare Infrastructure: Emerging economies are investing in advanced therapeutic centers and collaborations with global biotech firms to strengthen regenerative medicine capabilities.

Segments Covered in the Beverage Premix Market:

By Product Type (Cell-Based Products and Non-Cell-Based Products)

By Technology (Ex Vivo Culture, In Vivo Gene Modification, 3D Bioprinting, Nanotechnology, CRISPR and Genome Editing, and Scaffold-Based Techniques)

By Application ( Dermatology, Musculoskeletal, Immunology & Inflammation, Oncology, Cardiovascular, Ophthalmology, and Others.)

By End User (Hospitals and Clinics, Research Institutes, Pharmaceutical and Biotechnology Companies, Academic Institutes, and Contract Research Organizations (CROs))

Regional Analysis for Beverage Premix Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=cell-regeneration-medicine-market?sg

Major Key Players: Astellas Pharma Inc, Thermo Fisher Scientific Inc., Smith & Nephew plc, Integra LifeSciences Holdings Corporation, Organogenesis Holdings Inc, Stryker Corporation, Amgen Inc., F. Hoffmann, Roche Ltd, Baxter International Inc and Vertex Pharmaceuticals.

✅ Astellas Pharma Inc. - Active investor/collaborator in cell-therapy ecosystems (building pharma + automation partnerships and R&D capabilities), positioning Astellas as a growing strategic developer in cell regeneration rather than a dominant market-share incumbent.

✅ Thermo Fisher Scientific Inc. - A major enabling supplier for the cell-and-gene supply chain (large commercial lab/bioprocessing footprint); Thermo Fisher posts very large overall revenues (~USD 42.9B FY2024) and is estimated to hold a double-digit share (reported ~11-14% range) of the cell/gene therapy manufacturing equipment & services market.

✅ Smith & Nephew plc - A leading med-tech in tissue repair and advanced wound management (core regenerative product lines); reports large recurring medtech revenues (Q3 2025 revenue reported ≈ USD 1.50B) with advanced wound care / tissue-repair businesses anchoring its regenerative segment.

✅ Integra LifeSciences - A focused regenerative / wound-care and surgical-implant specialist with reported annual revenues in the low-hundreds of millions (FY2024 roughly USD ~440M), supplying skin substitutes, scaffolds and regenerative products - a mid-sized specialist in the broader regeneration market.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.